BRIEF published on 11/01/2024 at 18:23, 1 year 4 months ago GenSight Biologics Secures €2.8 Million Financing Warrants Financing Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 11/01/2024 at 18:18, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics announces a €2.8 million financing through a Reserved Offering. Funding to extend cash runway for developing gene therapies. Details on investor support and future plans Investors Financing GenSight Biologics Gene Therapies Reserved Offering
BRIEF published on 10/24/2024 at 21:13, 1 year 4 months ago GenSight Biologics Discloses Cash Position, Advances on LUMEVOQ® Treasury Funding LUMEVOQ® ANSM Compassionate Access
PRESS RELEASE published on 10/24/2024 at 21:08, 1 year 4 months ago Inside Information / News release on accounts, results GenSight Biologics reports €3.4 million cash position as of September 30, 2024, updates on LUMEVOQ® drug product status, and financial discussions for future funding Cash Position Financial Update GenSight Biologics LUMEVOQ AAC Resumption
BRIEF published on 10/17/2024 at 07:35, 1 year 4 months ago GenSight Biologics Presents LUMEVOQ® Data at AAO 2024 Gene Therapy GenSight Biologics LUMEVOQ® LHON AAO 2024
PRESS RELEASE published on 10/17/2024 at 07:30, 1 year 4 months ago Inside Information / Other news releases GenSight Biologics to present scientific updates on LUMEVOQ® gene therapy at AAO 2024, including real-world experience and long-term outcomes for LHON patients Gene Therapy GenSight Biologics LHON LUMEVOQ AAO 2024
PRESS RELEASE published on 09/27/2024 at 11:24, 1 year 5 months ago HALF-YEAR_FINANCIAL_REPORT_JUNE_2024
BRIEF published on 09/23/2024 at 19:41, 1 year 5 months ago GenSight Biologics Reports Interim Financial Results for H1 2024 Financial Results Cash Management LUMEVOQ® Early Access Program R&D Expenses
PRESS RELEASE published on 09/23/2024 at 19:36, 1 year 5 months ago Inside Information / News release on accounts, results GenSight Biologics reports interim financial results for the first half of 2024, highlighting optimized cash management, extension of cash runway, and upcoming LUMEVOQ® drug product release Cash Management GenSight Biologics Interim Financial Results LUMEVOQ® Drug Product Release
BRIEF published on 09/17/2024 at 14:45, 1 year 5 months ago Goldman Sachs sells its GENSIGHT BIOLOGICS SA shares Euronext Paris Goldman Sachs Crossing Thresholds Transfer Of Shares GenSight Biologics
Published on 03/16/2026 at 13:00, 23 minutes ago Aeonian Commences Inaugural Drill Program at the Jake Zone, Koocanusa Copper-Silver Project, Southeastern British Columbia
Published on 03/16/2026 at 12:30, 53 minutes ago Sterling Metals Intersects 235.5m at 0.42% Cu and 0.042 g/t Au including 32.75m at 1.31% Cu and 0.11 g/t Au and Discovers New Bornite-Covellite Zone
Published on 03/16/2026 at 12:30, 53 minutes ago Electric Metals (USA) Limited Announces Agreement to Sell Non-Core Nevada Silver Assets
Published on 03/16/2026 at 12:30, 53 minutes ago Eskay Continues to Build its EXPLORATION TEAM for the 2026 Season
Published on 03/16/2026 at 12:30, 53 minutes ago Digi Power X Provides Clarification on US Data Centers Transaction
Published on 03/16/2026 at 12:21, 1 hour 1 minute ago North Peak Announces Initial $4.38 Million Closing for Previously Announced Non-Brokered Private Placement
Published on 03/16/2026 at 12:18, 1 hour 4 minutes ago Commerzbank takes note of UniCredit’s unsolicited takeover attempt
Published on 03/16/2026 at 12:15, 1 hour 7 minutes ago Commerzbank takes note of UniCredit’s unsolicited takeover attempt
Published on 03/16/2026 at 12:12, 1 hour 10 minutes ago Aroundtown SA: Release of a capital market information
Published on 03/16/2026 at 08:30, 4 hours 53 minutes ago CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 17 hours ago Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 19 hours ago Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 5 hours ago BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 19 hours ago NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS
